Portfolio evolution helps Danaher post "solid" Q3
This article was originally published in Clinica
Executive Summary
Jefferies analyst Brandon Couillard has raised his 2014 earnings forecast for Danaher to $3.80 per share, from $3.75, on the back of a “solid” third quarter. He noted that the company’s Q3 “core EPS of $0.84 was $0.01 ahead of consensus on better than expected core revenue growth [3% vs his estimate of 2.5%] and profitability experiences.” Danaher’s Q3 sales grew 6% to $4.67bn on a reported basis, up 3% at constant currency. The company has benefited from “portfolio repositioning efforts,” the analyst added, and “expansion in its life sciences & diagnostics and dental franchises helped mitigate the effects of muted trends in certain industrial-oriented areas, which appear to be stabilizing.” Danaher was recently boosted by the approval of a key troponin test, used as a marker of heart attack, developed by its Beckman Coulter subsidiary (www.clinica.co.uk, 27 September 2013). There has also been speculation that Danaher could be in the running to acquire Johnson & Johnson’s Ortho Clinical Diagnostics unit (www.clinica.co.uk, 11 September 2013).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.